Skip to main content
Log in

NPS 1506, a moderate affinity uncompetitive NMDA receptor antagonist: preclinical summary and clinical experience

  • Short Comment
  • Published:
Amino Acids Aims and scope Submit manuscript

Summary.

NPS Pharmaceuticals, Inc. (NPS) has synthesized a series of open-channel blockers with varying potencies at the NMDA receptor. NPS 1506 (Fig. 1) is a moderate affinity antagonist that inhibits NMDA/glycine-induced increases in cytosolic calcium in cultured rat cerebellar granule cells (IC50 = 476 nM) and displaces the binding of [3H]MK-801 to rat cortical membranes (IC50 = 664 nM).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received August 31, 1999 Accepted September 20, 1999

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mueller, A., Artman, L., Balandrin, M. et al. NPS 1506, a moderate affinity uncompetitive NMDA receptor antagonist: preclinical summary and clinical experience. Amino Acids 19, 177–179 (2000). https://doi.org/10.1007/s007260070047

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s007260070047

Navigation